A new report released by Pharmaceutical Research and Manufacturers of America (PhRMA) outlines 37 new Parkinson’s disease drugs either in clinical trials or awaiting review by the Food and Drug Administration.
According to the report, several of the 37 medications are “disease modifying therapies focused on protecting the brain cells in an attempt to halt disease progression, or treatments aimed at generating new cells or repairing damaged nerve cells.”
Some examples of potential advances include:
- A gene therapy that targets the part of the brain that controls movement.
- A new medicine that targets a receptor found in the brain where degeneration and abnormality are often seen in Parkinson’s disease.
- New delivery mechanisms of approved treatments, including an intranasal formulation and an intestinal gel.
Click here to read the full report, which includes a full list of the 37 new drugs.
PAN, along with The Michael J. Fox Foundation for Parkinson’s Research, the National Parkinson Foundation, The Parkinson Alliance, and the Parkinson’s Disease Foundation released a joint statement on March 24 applauding biopharmaceutical research companies for developing 37 new Parkinson’s disease drugs, but called for more research to find effective medications that would target the disease directly.
Amy Comstock Rick, CEO of PAN, also wrote a post for PhRMA’s Conversations blog answering the question: What is the greatest issue facing Parkinson’s patients today, and what can be done to accelerate the research and development of new therapies to help them? Read Amy’s answer and join others who have also answered this question by adding your comment here.